Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy

Neurodegenerative Diseases

Volumn 5, Issue 6, 2008, Pages 339-346

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Progressive supranuclear palsy; PSP parkinsonism; Regional tau pathologies; Richardson's syndrome; Typical atypical phenotypes

Indexed keywords

TAU PROTEIN;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; AUTOPSY; BODY EQUILIBRIUM; BRADYKINESIA; CEREBELLUM DISEASE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSKINESIA; DYSPHAGIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FALLING; FEMALE; GAZE PARALYSIS; GLOBUS PALLIDUS; HISTOPATHOLOGY; HUMAN; HYPERSALIVATION; IMMUNOHISTOCHEMISTRY; LIMBIC CORTEX; MALE; NEOCORTEX; NEUROPATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN LOCALIZATION; PYRAMIDAL SIGN; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RICHARDSON SYNDROME; RIGIDITY; SACCADIC EYE MOVEMENT; SENSORY DYSFUNCTION; SPEECH DISORDER; STAINING; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SYMPTOMATOLOGY; TREMOR; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; COHORT STUDIES; FEMALE; GLOBUS PALLIDUS; HUMANS; IMMUNOHISTOCHEMISTRY; LEWY BODIES; MALE; MIDDLE AGED; NEURONS; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 49849095938     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000121388     Document Type: Article

References (36)

1. Bower JH, Maraganore DM, McDonnell SK, Rocca WA: Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49:1284-1288.
2. Schrag A, Ben-Shlomo Y, Quinn NP: Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354:1771-1775.
3. Nath U, Ben-Shlomo Y, Thomson RG, et al: The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001;124:1438-1449.
4. Litvan I: Progressive supranuclear palsy; in Litvan I (ed): Current Clinical Neurology: Atypical Parkinsonian Disorders - Clinical and Research Aspects. Totowa, Humana Press, 2005, pp 287-308.
5. Houlden H, Baker M, Morris HR, et al: Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702-1706.
6. Tsuboi Y, Josephs KA, Boeve BF, et al: Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord 2005;20:982-988.
7. Josephs KA, Boeve BF, Duffy JR, et al: Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 2005;11:283-296.
8. Dickson D, Rademakers R, Hutton ML: Progressive supranuclear palsy: pathology and genetics. Brain Pathol 2007;17:74-82.
9. Hauw JJ, Agid Y: Progressive supranuclear palsy (PSP) or Steele-Richardson-Olszewski disease; in Dickson D (ed): Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel, ISN Neuropath Press, 2003, pp 103-114.
10. Hauw JJ, Daniel SE, Dickson D, et al: Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-2019.
11. Duyckaerts C: Atypical parkinsonian disorders; in Litvan I (ed): Current Clinical Neurology: Atypical Parkinsonian Disorders - Clinical and Research Aspects. Totowa, Humana Press, 2005, pp 111-138.
12. Williams DR, de Silva R, Paviour DC, et al: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247-1258.
13. Josephs KA, Dickson DW: Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 2003;18:1018-1026.
14. Williams DR, Holton JL, Strand K, de Silva R, Lees AJ, Revesz T: Differences in tau load are associated with different clinical phenotypes in progressive supranuclear palsy observations. Neuropathol Appl Neurobiol 2007;33:256-257.
15. Williams DR, Holton JL, Lees AJ, Revesz T: Severity of tau deposition in progressive supranuclear palsy is associated with clinical phenotype (abstract). Mov Disord 2007;22(suppl 16):S260.
16. Williams DR, Holton JL, Strand C, et al: Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007;130:1566-1576.
17. Williams DR, Pittman AM, Revesz T, Lees AJ, de Silva R: Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy. Mov Disord 2007;22:895-897.
18. Jellinger K, Riederer P, Tomonaga M: Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl 1980;16:111-128.
19. Jellinger KA, Attems J: Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol (Berl) 2007;113:107-117.
20. Mirra SS, Heyman A, McKeel D, et al: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
21. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
22. Uchikado H, DelleDonne A, Ahmed Z, Dickson DW: Lewy bodies in progressive supranuclear palsy represent an independent disease process. J Neuropathol Exp Neurol 2006;65:387-395.
23. Tsuboi Y, Ahlskog JE, Apaydin H, Parisi JE, Dickson DW: Lewy bodies are not increased in progressive supranuclear palsy compared with normal controls. Neurology 2001;57:1675-1678.
24. Mori H, Oda M, Komori T, et al: Lewy bodies in progressive supranuclear palsy. Acta Neuropathol (Berl) 2002;104:273-278.
25. Josephs KA, Ishizawa T, Tsuboi Y, Cookson N, Dickson DW: A clinicopathological study of vascular progressive supranuclear palsy: a multi-infarct disorder presenting as progressive supranuclear palsy. Arch Neurol 2002;59:1597-1601.
26. Richardson JC, Steele J, Olszewski J: Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of 'heterogenous system degeneration'. Trans Am Neurol Assoc 1963;88:25-29.
27. Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ: Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003;60:910-916.
28. Maher ER, Lees AJ: The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986;36:1005-1008.
29. Revesz T, Sangha H, Daniel SE: The nucleus raphe interpositus in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Brain 1996;119:1137-1143.
30. Daniel SE, de Bruin VM, Lees AJ: The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995;118:759-770.
31. Birdi S, Rajput AH, Fenton M, et al: Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002;17:1255-1264.
32. Morris HR, Gibb G, Katzenschlager R, et al: Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain 2002;125:969-975.
33. Wenning GK, Jellinger KA: The role of alpha-synuclein and tau in neurodegenerative movement disorders. Curr Opin Neurol 2005;18:357-362.
34. Jellinger KA: Advances in our understanding of neurodegeneration; in Qureshi GA, Parvez SH (eds): Oxidative Stress and Neurodegenerative Disorders. Amsterdam, Elsevier, 2007, pp 1-58.
35. Armstrong RA, Lantos PL, Cairns NG: Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical regions of eight cases. J Neural Transm 2007;114:1569-1577.
36. Urasaki K, Kuriki K, Namerikawa M, et al: An autopsy case of Alzheimer's disease with a progressive supranuclear palsy overlap. Neuropathology 2000;20:233-238.